References
- Alter M J, Kruszon‐Moran D, Nainan O V, McQuillan G M, Gao F, Moyer L A, Kaslow R A, Margolis H S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–562, [PUBMED], [INFOTRIEVE], [CSA]
- Seeff L B. Natural history of hepatitis C. Am J Med 1999; 107(6B)10S–15S, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J. Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. Br Med J 1999; 319: 290–291
- Dhopesh V P, Taylor K R, Burke M. Survey of hepatitis B and C in an addiction treatment unit. Am J Drug Alcohol Abuse 2000; 26: 703–707, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Simonetti R G, Camma C, Fiorello F. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: a case‐control study. Ann Intern Med 1992; 116: 97–102, [PUBMED], [INFOTRIEVE], [CSA]
- Kim W R. The burden of hepatitis C in the United States. Hepatology 2002; 36(5 suppl 1)S30–S34, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zaman A, Fennerty M B, Keeffe E B. Peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2003, 7: 661–670, [CROSSREF]
- Baker D E. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev Gastroenterol Disord 2003; 3(2)93–109, [PUBMED], [INFOTRIEVE], [CSA]
- Arif A, Levine R A, Sanderson S O, Bank L, Velu R P, Shah A, Mahl T C, Gregory D H. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003; 48(7)1425–1430, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Patel K, McHutchison J G. Current therapies for chronic hepatitis C: drug combination achieves sustained response in more than half of patients. Postgrad Med 2003; 114(1), pp. 48–52, 57–59, 62
- Salomon J A, Weinstein M C, Hammitt J K, Goldie S J. Cost‐effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290(2)228–237, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hagan H, Thiede J, Weiss N S, Hopkins S G, Duchin J S, Alexander E R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42–46, [PUBMED], [INFOTRIEVE], [CSA]
- Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S–9S, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Alter M J. Prevention of spread of hepatitis C. Hepatology 2002; 36(5 suppl 1)S93–S98, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Koblin B A, Factor S H, Wu Y, Vlahov D. Hepatitis C virus infection among noninjecting drug users in New York City. J Med Virol 2003; 70(3)387–390, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Page‐Shafer K A, Cahoon‐Young B, Klausner J D, Morrow S, Molitor F, Ruiz J, McFarland W. Young women's survey team. Hepatitis C virus infection in young, low income women: the role of sexually transmitted infection as a potential cofactor for HCV. Am J Public Health 2002; 92: 670–676, [CSA]
- Askari F K. Hepatitis C: The Silent Epidemic. Perseus Publishing, Cambridge, MA 1999
- Rosenberg S D, Goodman L A, Osher F C. Prevalence of HIV, hepatitis B and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91: 42–46, [CSA]
- Rosenblum A, Nuttbrock L, McQuistion H L, Magura S, Joseph H. Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis, 20: 15–25, [CSA]
- Tortu S, Neaigus A, McMahon J, Hagen D. Hepatitis C among non‐injecting drug users: a report. Subst Use Misuse 2001; 36: 523–534, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kwiatkowski C F, Fortuin E, Corsi K, Booth R E. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002; 97: 1289–1294, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bae J P. Assessing the need, use, and developments in mental health/substance abuse care. Health Care Financ Rev 1997; 18: 1–4, [PUBMED], [INFOTRIEVE]
- Chitwood D D, McBride D C, French M T, Comerford M. Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. Subst Use Misuse 1999; 34: 727–746, [PUBMED], [INFOTRIEVE], [CSA]
- Contoreggi C, Rexroad V E, Lange W R. Current management of infectious complications in the injecting drug user. J Subst Abuse Treat 1998; 15: 95–106, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McCarthy J J, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis 2001; 20: 19–31, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Carter H, Robinson G, Hanlon C, Hailwood C, Massarotto A. Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. N Z Med J 2001; 114(1136)324–326, [PUBMED], [INFOTRIEVE]
- Strauss S M, Falkin G P, Vassilev Z P, Des Jarlais D C, Astone J. A nationwide survey of hepatitis C services provided by drug treatment programs. J Subst Abuse Treat 2002; 22: 55–62, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Astone J, Strauss S M, Vassilev Z P, Des Jarlais D C. Provision of hepatitis C education in a nationwide sample of drug treatment programs. J Drug Educ 2003; 33: 107–117, [PUBMED], [INFOTRIEVE], [CSA]
- Strauss S M, Astone J, Vassilev Z P, Des Jarlais D C, Hagan H. Gaps in the drug‐free and methadone maintenance treatment program response to hepatitis C. J Subst Abuse Treat 2003; 24: 291–297, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Becker B, Marshall H. Sociometric location and innovativeness: reformulation location and extension of the diffusion model. Am Sociol Rev 1970; 35: 262–282
- Clapp J D. Organizational factors related to AIDS/HIV education in outpatient substance abuse treatment units. J Health Soc Policy 1998; 9: 1–13, [PUBMED], [INFOTRIEVE], [CSA]
- Hage J, Dewar R. Elite values versus organizational structure in predicting innovation. Adm Sci Q 1973; 18: 279–290, [CSA]
- D'Aunno T, Vaughn T E, McElroy P. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. J Health Soc Behav 1999; 40: 175–192, [PUBMED], [INFOTRIEVE], [CSA]
- Wimbush J, Amicarelli A, Stein M D. Does HIV test result influence methadone maintenance treatment retention?. J Subst Abuse Treat 1996; 8(2)263–269
- Gonzalez I, Rosenthal M S, Bigler M O, Alper K, Geringer W. HIV antibody testing and client retention in the therapeutic community. J Subst Abuse Treat 1994; 11(5)481–488, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sylvestre D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67(2)117–123, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Edlin B R, Seal K H, Lorvick J, Kral A H, Ciccarone D H, Morre L D, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit‐drug users?. J Subst Abuse Treat 2003; 24(1)81–88, [CROSSREF], [CSA]
- National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002—June 10–12, 2002. Hepatology 2002; 36: S3–S20, [CROSSREF]
- Anglin M D, Hser Y I, Grella C E. Drug addiction and treatment careers among clients in the drug abuse treatment outcome study (DATOS). Psychol Addict Behav 1997; 11: 308–323, [CROSSREF], [CSA]
- Etheridge R M, Hubbard R L, Anderson J, Craddock S G, Flynn P M. Treatment structure and program services in the drug abuse treatment outcome study (DATOS). Psychol Addict Behav 1997; 11: 244–260, [CROSSREF], [CSA]
- Broome K M, Simpson D D, Joe G W. Patient and program attributes related to treatment process indicators in DATOS. Drug Alcohol Depend 1999; 57(2)127–135, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schildhaus S, Gerstein D, Dugoni B, Brittingham A, Cerbone F. Services research outcome study: explanation of treatment effectiveness, using individual‐level and programmatic variables. Subst Use Misuse 2000; 35(12–14)1879–1910, [PUBMED], [INFOTRIEVE], [CSA]
- Cronbach L J. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297–334
- Friedmann P D, Lemon S C, Durkin E M, D'Aunno T A. Trends in comprehensive service availability in outpatient drug abuse treatment. J Subst Abuse Treat 2003; 24: 81–88, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rogers E M. Diffusion of Innovations4th ed. Free Press, New York 1995
- DiMaggio P J, Powell W W. The iron cage revisited: institutional isomorphism and collective rationality in organizational fields. Adm Sci Q 1983; 48: 147–160
- Meyer J W, Rowan B. Institutional organization: formal structure as myth and ceremony. Am J Sociol 1977; 83: 340–363, [CROSSREF], [CSA]
- Scott W R. Innovations and Organizations. Sage, Thousand Oaks, CA 1995
- Edlin B R. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36(5)210–219, [CROSSREF]
- Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot‐Peignoux M, Degott C, Valla D, Erlinger S, Rueff B. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27(6)1717–1722, [PUBMED], [INFOTRIEVE], [CROSSREF]